# EDGAR Filing Document

**Accession Number:** 0001497253
**File Stem:** 0001193125-25-324794
**Filing Date:** 2025-12
**Character Count:** 8679
**Document Hash:** 25b227eebf76036860a4dad7982a9204
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-25-324794.hdr.sgml**: 20251218

**ACCESSION NUMBER**: 0001193125-25-324794

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 10

**CONFORMED PERIOD OF REPORT**: 20251216

**ITEM INFORMATION**: Submission of Matters to a Vote of Security Holders

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20251218

**DATE AS OF CHANGE**: 20251218

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** VivoSim Labs, INC.
- **CENTRAL INDEX KEY:** 0001497253
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 271488943
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 0331

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-35996
- **FILM NUMBER:** 251583060

**BUSINESS ADDRESS:**
- **STREET 1:** 11555 SORRENTO VALLEY ROAD
- **STREET 2:** SUITE 100
- **CITY:** SAN DIEGO
- **STATE:** CA
- **ZIP:** 92121
- **BUSINESS PHONE:** 858-224-1000

**MAIL ADDRESS:**
- **STREET 1:** 11555 SORRENTO VALLEY ROAD
- **STREET 2:** SUITE 100
- **CITY:** SAN DIEGO
- **STATE:** CA
- **ZIP:** 92121

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** ORGANOVO HOLDINGS, INC.
- **DATE OF NAME CHANGE:** 20120104

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** REAL ESTATE RESTORATION & RENTAL, INC.
- **DATE OF NAME CHANGE:** 20100722

?xml version='1.0' encoding='ASCII'? 8-K

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, D.C. 20549**

------

## FORM 8-K

------

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported):** December 16, 2025<br>

------

VivoSim Labs, Inc.

**(Exact name of Registrant as Specified in Its Charter)**

------

---

| | | |
|:---|:---|:---|
| Delaware | 001-35996 | 27-1488943 |
| **(State or Other Jurisdiction<br>of Incorporation)** | **(Commission File Number)** | **(IRS Employer<br>Identification No.)** |
| 11555 Sorrento Valley Rd<br>Suite 100 |  |  |
| San Diego**,** California |  | 92121 |
| **(Address of Principal Executive Offices)** |  | **(Zip Code)** |

---

**Registrant's Telephone Number, Including Area Code:** (858) 224-1000<br>

**(Former Name or Former Address, if Changed Since Last Report)**

------

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Securities registered pursuant to Section 12(b) of the Act:**

---

| | | |
|:---|:---|:---|
| **<br>Title of each class** | **Trading<br>Symbol(s)** | **<br>Name of each exchange on which registered** |
| Common Stock, $0.001 par value | VIVS | The Nasdaq Stock Market LLC |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

------

## Item 5.07 Submission of Matters to a Vote of Security Holders.
On December 16, 2025, VivoSim Labs, Inc. (the "Company") held its 2025 Annual Meeting of Stockholders (the "Annual Meeting"). Of the 2,607,962 shares of the Company's common stock, par value $0.001 per share (the "Common Stock"), issued and outstanding as of the October 17, 2025 record date, 972,769 shares, or 37.29%, constituting a quorum, were represented at the Annual Meeting either virtually or by proxy.

A description of each proposal voted upon at the Annual Meeting is described in the Company's definitive proxy statement filed with the Securities and Exchange Commission on November 3, 2025 (the "Proxy Statement").Set forth below is a brief description of each proposal voted upon at the Annual Meeting and the voting results with respect to each proposal.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1) <u>Election of Directors</u>. The Company's stockholders elected Douglas Jay Cohen and David Gobel as Class II directors, each to hold office until the 2028 Annual Meeting of Stockholders and until his respective successor is elected and qualified. The following table shows the tabulation of the votes cast "For" and "Withheld" for each of Mr. Cohen and Mr. Gobel as well as the "Broker Non-Votes" submitted for this proposal:

---

| | | | |
|:---|:---|:---|:---|
| **Director** | **For** | **Withheld** | **Broker Non-Votes** |
| &nbsp;&nbsp;&nbsp;Douglas Jay Cohen | 212,079 | 15,531 | 745,159 |

---

---

| | | | |
|:---|:---|:---|:---|
| **Director** | **For** | **Withheld** | **Broker Non-Votes** |
| &nbsp;&nbsp;&nbsp;David Gobel | 212,420 | 15,190 | 745,159 |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(2) <u>Ratification of Auditors</u>. The Company's stockholders ratified the appointment of Rosenberg Rich Baker Berman P.A. as the Company's independent registered public accounting firm for the fiscal year ending March 31, 2026, with the approval of 97.91% of the votes cast. The following table shows the tabulation of the votes cast "For" and "Against" this proposal as well as the "Abstentions" submitted for this proposal:

---

| | | |
|:---|:---|:---|
| **For** | **Against** | **Abstentions** |
| &nbsp;&nbsp;&nbsp;935,525 | 19,923 | 17,321 |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(3) <u>Advisory Vote on the Compensation of Named Executive Officers</u>. The Company's stockholders, on a non-binding, advisory basis, approved the compensation of the Company's named executive officers as disclosed in the Proxy Statement, with the approval of 89.97% of the votes cast. The following table shows the tabulation of the votes cast "For" and "Against" this proposal as well as the "Abstentions" and "Broker Non-Votes" submitted for this proposal:

---

| | | | |
|:---|:---|:---|:---|
| **For** | **Against** | **Abstentions** | **Broker Non-Votes** |
| &nbsp;&nbsp;&nbsp;193,240 | 21,542 | 12,828 | 745,159 |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(4) <u>Frequency of Advisory Vote on Executive Compensation</u>. The Company's stockholders approved the frequency, on a non-binding, advisory basis, of "one year" on the frequency of future stockholder votes on executive compensation, with 97.17% of the votes cast for "one year". The following table shows the tabulation of the votes cast for "one year", "two years" and "three years", as well as the "Abstentions" submitted for this proposal:

---

| | | | |
|:---|:---|:---|:---|
| **One Year** | **Two Years** | **Three Years** | **Abstentions** |
| &nbsp;&nbsp;&nbsp;207,095 | 974 | 5,053 | 14,488 |

---

In light of the advisory vote of the Company's stockholders to hold future advisory votes on the compensation of the Company's named executive officers every one year, the Company has determined that it will hold future advisory votes on the compensation of the Company's named executive officers on an annual basis until the next stockholder advisory vote on the frequency of future advisory votes on the compensation of the Company's named executive officers.

No other items were presented for stockholder approval at the Annual Meeting.

------

## Item 9.01 Financial Statements and Exhibits.

---

| | |
|:---|:---|
| Exhibit<br>No. | Description |
| 104 | Cover Page Interactive Data File, formatted in Inline Extensible Business Reporting Language (iXBRL). |

---

------

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | | |
|:---|:---|:---|:---|
|  |  |  | VivoSim Labs, Inc. |
| Date: | December 18, 2025 | By:  | /s/ Keith Murphy |
|  |  |  | Name: Keith Murphy<br>Title: Executive Chairman |

---

------